WHO TRS (Technical Report Series) 957, 2010 Annex 3


WHO TRS (Technical Report Series) 957, 2010 Annex 3

WHO good manufacturing practices for pharmaceutical products containing hazardous substances

1. Introduction:

1.1 These guidelines set out good practices applicable to facilities handling pharmaceutical products (including active pharmaceutical ingredients (APIs)) that contain hazardous substances such as certain hormones, steroids or cytotoxins. They do not replace national legislation for protection of the environment and personnel. Other WHO guides to good manufacturing practices (GMP) and regulations need to be observed in addition to the workers’ safety criteria (1–4).

1.2 These guidelines are to be read in conjunction with other WHO GMP guidelines with respect to building finishes and general services installations, among others. See the reference list for relevant publications which serve as additional background material. The primary focus of these guidelines is on the air-conditioning and ventilation systems of the facility; however, the document also provides some guidance on personnel protection.

1.3 The areas to which this document applies include all zones where the handling of products could lead to cross-contamination, exposure of personnel, or discharge to the environment. This includes research and development facilities, and the sites of API manufacturing and storage and of finished product manufacturing.

1.4 Where possible products should be manufactured in closed systems.

Click on the following title for full details: pdf 

Table of contents

WHO TRS (Technical Report Series) 957, 2010 Annex 3:

Post a Comment


Post a Comment (0)